se of medication for preventing diabetes in obese pregnant wome
- Conditions
- Diabetes mellitus arises during pregnancy. Pregnancy complications.O24.4
- Registration Number
- RBR-9rpqdn
- Lead Sponsor
- niversidade da Região de Joinville Univille
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
With obesity diagnosis of pregnant women will be selected according to the criteria of the World Health Organization with BMI or greater than 30 kg / m2; aged over 18 years; singleton pregnancy; with screening for gestational diabetes mellitus (GDM) at the beginning of the negative pregnancy; gestational age less than 20 weeks; no pathology that interferes with glucose metabolism; no hypersensitivity to metformin hydrochloride or important drug allergy; history or presence of liver disease; renal or gastrointestinal or other conditions that interfere with the absorption, distribution, excretion or metabolism of the drug.
Losses following are deleted; intolerance drugs; desire of the pregnant woman; presence of risk to the fetus; allergy to metformin, mother's death and fetus.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of cases of Gestational Diabetes Mellitus in obese pregnant women who have made the use of metformin hydrochloride, 2 times a day (breakfast and dinner), the realization of the reduction will be performed by biochemical analysis through oral test of glucose tolerance (OGTT ) to be held over the gestational trimesters. It expects a 35% effectiveness in reducing cases of Gestational Diabetes Mellitus which will be proven through statistical tests and comparing the concentrations in the OGTT test and control groups.
- Secondary Outcome Measures
Name Time Method Decreased neonatal hypoglycemia in infants of obese pregnant women who have made the use of metformin hydrochloride during pregnancy. For evaluation of this variable will be held plasma glucose dosage of newborns according to protocol guidelines of the Brazilian Society of Pediatrics. For realization of the expected outcomes will be performed statistical tests and comparing the concentrations of plasma glucose in babies of mothers of test and control groups.